NL194865B - Werkwijze voor de bereiding van een niet-giftig hydrolyseproduct van een endotoxine en farmaceutisch preparaat dat een dergelijk hydrolyseproduct bevat. - Google Patents

Werkwijze voor de bereiding van een niet-giftig hydrolyseproduct van een endotoxine en farmaceutisch preparaat dat een dergelijk hydrolyseproduct bevat.

Info

Publication number
NL194865B
NL194865B NL8301842A NL8301842A NL194865B NL 194865 B NL194865 B NL 194865B NL 8301842 A NL8301842 A NL 8301842A NL 8301842 A NL8301842 A NL 8301842A NL 194865 B NL194865 B NL 194865B
Authority
NL
Netherlands
Prior art keywords
hydrolysis product
endotoxin
toxic
preparation
pharmaceutical preparation
Prior art date
Application number
NL8301842A
Other languages
English (en)
Other versions
NL8301842A (nl
NL194865C (nl
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of NL8301842A publication Critical patent/NL8301842A/nl
Publication of NL194865B publication Critical patent/NL194865B/nl
Application granted granted Critical
Publication of NL194865C publication Critical patent/NL194865C/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NL8301842A 1982-05-26 1983-05-25 Werkwijze voor de bereiding van een niet-giftig hydrolyseproduct van een endotoxine en farmaceutisch preparaat dat een dergelijk hydrolyseproduct bevat. NL194865C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/382,404 US4436727A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product
US38240482 1982-05-26

Publications (3)

Publication Number Publication Date
NL8301842A NL8301842A (nl) 1983-12-16
NL194865B true NL194865B (nl) 2003-01-06
NL194865C NL194865C (nl) 2003-05-06

Family

ID=23508804

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8301842A NL194865C (nl) 1982-05-26 1983-05-25 Werkwijze voor de bereiding van een niet-giftig hydrolyseproduct van een endotoxine en farmaceutisch preparaat dat een dergelijk hydrolyseproduct bevat.

Country Status (21)

Country Link
US (1) US4436727A (nl)
JP (2) JPS58216121A (nl)
KR (1) KR870000842B1 (nl)
AT (1) AT386337B (nl)
AU (1) AU556532B2 (nl)
BE (1) BE896822A (nl)
CA (1) CA1185899A (nl)
CH (1) CH661526A5 (nl)
DE (1) DE3318569A1 (nl)
DK (1) DK159275C (nl)
FI (1) FI76494C (nl)
FR (1) FR2527613B1 (nl)
GB (1) GB2122204B (nl)
HU (1) HU190491B (nl)
IL (1) IL68713A (nl)
IN (1) IN156144B (nl)
IT (1) IT1164242B (nl)
NL (1) NL194865C (nl)
NO (1) NO154864C (nl)
NZ (1) NZ204298A (nl)
SE (1) SE462017B (nl)

Families Citing this family (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPS61151157A (ja) * 1984-12-25 1986-07-09 Seiko Instr & Electronics Ltd タンパク質を加水分解する方法
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
JPH01141942U (nl) * 1988-03-24 1989-09-28
JPH01180041U (nl) * 1988-06-09 1989-12-25
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
JPH04501663A (ja) * 1988-09-23 1992-03-26 ユニバーシティ・オブ・サザン・カリフォルニア 黒色腫用免疫療法ワクチン
JPH02124341U (nl) * 1989-03-24 1990-10-12
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
IL134936A0 (en) 1997-09-10 2001-05-20 Vion Pharmaceuticals Inc Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO1999056776A2 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
PL346213A1 (en) 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US6013640A (en) * 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
KR20090088972A (ko) 1998-12-08 2009-08-20 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2000058456A2 (en) * 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
CZ20013527A3 (cs) 1999-04-02 2002-10-16 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
KR100922031B1 (ko) 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
JP2003512829A (ja) 1999-10-22 2003-04-08 アヴェンティス パストゥール リミテッド 改変型ｇｐ１００およびその使用
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
PT1265915E (pt) 2000-02-23 2011-02-07 Glaxosmithkline Biolog Sa Novos compostos
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1741782B1 (en) 2000-05-10 2011-06-22 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
EP1284740B1 (en) 2000-05-19 2008-05-21 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with monosaccharide-based compounds
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
ATE396265T1 (de) 2000-06-28 2008-06-15 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
KR100831139B1 (ko) 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
AU2002254901A1 (en) 2001-02-23 2002-10-03 Smithkline Beecham Biologicals S.A. Influenza vaccine formulations for intradermal delivery
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
WO2003005952A2 (en) 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
JP4601956B2 (ja) 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2003073827A2 (en) * 2002-02-28 2003-09-12 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
IL166178A0 (en) 2002-07-08 2006-01-15 Corixa Corp Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor
DK1537146T3 (da) 2002-07-15 2011-04-04 Univ Texas Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner
ATE414176T1 (de) 2002-07-18 2008-11-15 Univ Washington Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DK1589934T3 (en) 2003-01-06 2015-12-21 Corixa Corp Certain AMINOAL COOLER GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND APPLICATION
EP1660123B1 (en) 2003-09-02 2013-03-13 GlaxoSmithKline Biologicals s.a. Rotavirus vaccine
AU2005206388A1 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
US8409590B2 (en) * 2004-02-11 2013-04-02 Ligocyte Pharmaceuticals, Inc. Anthrax antigens and methods of use
CA2837748C (en) 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
WO2005117958A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006042156A2 (en) 2004-10-08 2006-04-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS represneted by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Modulation of replicative fitness by using less frequently used synonymous codons
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
EP1863529A1 (en) 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
CN101184504A (zh) 2005-03-31 2008-05-21 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
SI2457926T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
MX351247B (es) 2007-04-04 2017-10-05 Infectious Disease Res Institute Star Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
ES2539818T3 (es) 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
CA2695477A1 (en) 2007-08-13 2009-02-19 Glaxosmithkline Biologicals S.A. Infant plasmodium falciparum cs vaccines
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
NZ585556A (en) 2007-11-07 2012-07-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
US8637053B2 (en) 2007-12-03 2014-01-28 President And Fellows Of Harvard College Chlamydia antigens
BRPI0821532A2 (pt) 2007-12-24 2015-06-16 Id Biomedical Corp Quebec Antígenos de rsv recombinantes
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
CA2826508C (en) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
MX2011000668A (es) * 2008-07-18 2011-07-29 Id Biomedical Corp Quebec Antigenos quimericos polipeptidicos del virus sincitial respiratorio.
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
AU2009323682A1 (en) 2008-12-03 2010-06-10 Protea Vaccine Technologies Ltd. Glutamyl tRNA synthetase (GtS) fragments
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
SG2014014385A (en) 2009-02-17 2014-04-28 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
US20100316673A1 (en) 2009-06-16 2010-12-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
SI2445526T1 (sl) 2009-06-24 2016-08-31 Glaxosmithkline Biologicals S.A. Rekombinantni RSV antigeni
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
EP2477652B1 (en) 2009-09-16 2015-04-15 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
KR101958753B1 (ko) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. 인간 ｃｄ27에 결합하는 항체 및 이의 용도
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
BR112013000394B8 (pt) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Composição imunogênica, uso da mesma e método para preparar a referida composição
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
ES2635014T3 (es) 2010-10-15 2017-10-02 Glaxosmithkline Biologicals S.A. Antígeno gB del citomegalovirus
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
EP2637687B1 (en) 2010-11-08 2021-01-06 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
ME02380B (me) 2010-12-14 2016-06-20 Glaxosmithkline Biologicals Sa Mikobakterijska antigena kompozicija
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EP2723365A1 (en) 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN103958544B (zh) 2011-09-16 2018-04-24 Ucb医药有限公司 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
LT2811981T (lt) 2012-02-07 2019-06-10 Infectious Disease Research Institute Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
EP2833900B1 (en) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
RU2659149C2 (ru) 2012-08-03 2018-06-28 Инфекшес Дизиз Рисерч Инститьют Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
JP2015525794A (ja) 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
HUE043091T2 (hu) 2012-12-05 2019-08-28 Glaxosmithkline Biologicals Sa Immunogén készítmény
DK2941258T3 (da) 2013-01-02 2019-12-16 Decoy Biosystems Inc Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
KR20220139415A (ko) 2013-03-13 2022-10-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 선융합(prefusion) RSV F 단백질 및 이의 용도
WO2014140166A2 (en) 2013-03-15 2014-09-18 Glaxosmithkline Biologicals S.A. Vaccine
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EP3024476A1 (en) 2013-07-26 2016-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
MX2016003419A (es) 2013-09-19 2016-10-10 Novavax Inc Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
CN105992770B (zh) 2013-11-01 2021-06-25 奥斯陆大学 白蛋白的变体及其用途
EP3069138B1 (en) 2013-11-15 2019-01-09 Oslo Universitetssykehus HF Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
KR102411781B1 (ko) 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 단일 바이알 백신 제형
JP6797692B2 (ja) 2014-02-20 2020-12-09 バクサート インコーポレイテッド 小腸送達のための製剤
US10426828B2 (en) 2014-04-03 2019-10-01 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
US10420833B2 (en) 2014-05-19 2019-09-24 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
MX2016017094A (es) 2014-06-25 2017-05-03 Glaxosmithkline Biologicals Sa Composicion inmunógena de clostridium difficile.
JP6820830B2 (ja) 2014-07-18 2021-01-27 ユニヴァーシティ オブ ワシントン がんワクチン組成物およびその使用方法
ES2924988T3 (es) 2014-10-10 2022-10-13 Univ Michigan Regents Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
CA2971542A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
CN113456812B (zh) 2015-01-09 2024-08-20 埃图比克斯公司 用于联合免疫治疗的方法和组合物
WO2016141320A2 (en) 2015-03-05 2016-09-09 Northwestern University Non-neuroinvasive viruses and uses thereof
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
BR112017025316A2 (pt) 2015-05-26 2018-07-31 Ohio State Innovation Foundation estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
CN108024955A (zh) 2015-06-12 2018-05-11 瓦克萨特公司 用于rsv和诺如病毒抗原的小肠递送的制剂
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
JP2019511483A (ja) 2016-03-02 2019-04-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 免疫療法のためのｓｔｉｎｇ活性化ナノワクチン
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
CN116239693A (zh) 2016-03-14 2023-06-09 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
MA44723A (fr) 2016-04-18 2019-02-27 Celldex Therapeutics Inc Anticorps agonistes se liant au cd40 humain et leurs utilisations
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
DK3458475T3 (da) 2016-05-16 2022-09-12 Access To Advanced Health Inst Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder
MX2018014270A (es) 2016-05-21 2019-02-14 Infectious Disease Res Inst Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
US20200282032A1 (en) 2016-05-27 2020-09-10 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
IL298227B2 (en) 2016-06-01 2024-09-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
WO2018013820A1 (en) 2016-07-13 2018-01-18 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
CA3034124A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CA3036218A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018104313A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN118085055A (zh) 2017-04-19 2024-05-28 生物医学研究所 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
CN110621339A (zh) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
EP3630176A1 (en) 2017-05-30 2020-04-08 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
JP2020524143A (ja) 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
EP3678695A1 (en) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US11591364B2 (en) 2017-12-01 2023-02-28 Glaxosmithkline Biologicals Sa Saponin purification
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CN111836639A (zh) 2018-01-26 2020-10-27 河谷细胞有限公司 用于联合癌症疫苗和免疫辅助疗法的组合物和方法
TW202003023A (zh) 2018-03-12 2020-01-16 美商詹森藥物公司 針對尿路感染之疫苗
EP3781265A2 (en) 2018-04-17 2021-02-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CN112638936A (zh) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
CA3106304A1 (en) 2018-07-31 2020-02-06 Glaxosmithkline Biologicals Sa Antigen purification method
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
US20220339281A1 (en) 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
JP2022532944A (ja) 2019-05-25 2022-07-20 アクセス ツー アドバンスト ヘルス インスティチュート アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
US20220273789A1 (en) 2019-07-21 2022-09-01 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021048081A1 (en) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
WO2021067785A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V Staphylococcus peptides and methods of use
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
EP4077356A1 (en) 2019-12-19 2022-10-26 GlaxoSmithKline Biologicals SA S. aureus antigens and compositions thereof
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
WO2021224205A1 (en) 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
WO2021245025A1 (en) 2020-06-01 2021-12-09 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
EP4188427A1 (en) 2020-08-03 2023-06-07 GlaxoSmithKline Biologicals S.A. Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
CA3202549A1 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
MX2023006769A (es) 2020-12-09 2023-08-18 Glaxosmithkline Biologicals Sa Modificacion de saponinas.
MX2023007596A (es) 2020-12-24 2024-02-23 Plant Bioscience Ltd Metodos y enzimas para la producción de derivados del ácido quillaico.
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
JP2024514074A (ja) 2021-04-01 2024-03-28 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｅ．ｃｏｌｉ ｏ１８バイオコンジュゲートの産生
EP4320159A1 (en) 2021-04-09 2024-02-14 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023180677A1 (en) 2022-03-25 2023-09-28 Plant Bioscience Limited Biosynthesis
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE185031C (nl) *
DE472221C (de) * 1924-04-01 1929-02-25 Kalle & Co Akt Ges Verfahren zur Gewinnung der toxischen Komponenten aus den Aufschluessen von Bakterien
FR2393065A1 (fr) * 1977-05-31 1978-12-29 Merieux Inst Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis

Also Published As

Publication number Publication date
AU556532B2 (en) 1986-11-06
FR2527613B1 (fr) 1987-02-27
AT386337B (de) 1988-08-10
GB2122204A (en) 1984-01-11
BE896822A (fr) 1983-09-16
JPH042573B2 (nl) 1992-01-20
FI831749A0 (fi) 1983-05-18
KR870000842B1 (ko) 1987-04-25
NL8301842A (nl) 1983-12-16
NO831855L (no) 1983-11-28
IL68713A (en) 1986-02-28
IN156144B (nl) 1985-05-25
NO154864B (no) 1986-09-29
JPS58216121A (ja) 1983-12-15
CH661526A5 (de) 1987-07-31
ATA189483A (de) 1988-01-15
IT8321287A0 (it) 1983-05-25
DE3318569C2 (nl) 1987-10-29
SE8302774D0 (sv) 1983-05-18
GB2122204B (en) 1985-12-24
DK221883D0 (da) 1983-05-18
NZ204298A (en) 1986-10-08
JPS6313968B2 (nl) 1988-03-29
IL68713A0 (en) 1983-09-30
NO154864C (no) 1987-01-07
JPS6345225A (ja) 1988-02-26
FR2527613A1 (fr) 1983-12-02
DK221883A (da) 1983-11-27
DE3318569A1 (de) 1984-01-12
CA1185899A (en) 1985-04-23
IT1164242B (it) 1987-04-08
GB8313253D0 (en) 1983-06-22
NL194865C (nl) 2003-05-06
HU190491B (en) 1986-09-29
KR840004510A (ko) 1984-10-22
FI831749L (fi) 1983-11-27
DK159275B (da) 1990-09-24
SE462017B (sv) 1990-04-30
SE8302774L (sv) 1983-11-27
AU1461483A (en) 1983-12-01
DK159275C (da) 1991-02-18
FI76494B (fi) 1988-07-29
US4436727A (en) 1984-03-13
FI76494C (fi) 1988-11-10

Similar Documents

Publication Publication Date Title
NL194865B (nl) Werkwijze voor de bereiding van een niet-giftig hydrolyseproduct van een endotoxine en farmaceutisch preparaat dat een dergelijk hydrolyseproduct bevat.
IT8224886A0 (it) Involucro per prodotti da fumare emetodo di sua preparazione.
AU521699B2 (en) Solid oral pharmaceutical product
NL191051C (nl) Werkwijze voor de bereiding van een W/O/W-emulsie voor voedingsmiddelen.
NL193132B (nl) Werkwijze voor de bereiding van een preparaat dat tryptofan en/of threonine omvat.
NL190844C (nl) Sulfoniumverbindingen, werkwijzen voor de bereiding van deze verbindingen en farmaceutische preparaten, die deze verbindingen bevatten.
NL190334C (nl) Werkwijze voor de bereiding van polyfenyleenoxyden.
NL7801367A (nl) Werkwijze voor de bereiding en afscheiding van p-xyleen.
NL7614567A (nl) Werkwijze ter bereiding van een geneesmiddel en werkwijze ter bereiding van de geneeskrachtige verbinding.
NL930078I1 (nl) Aminederivaten werkwijze voor de bereiding daarvanen farmaceutische preparaten die deze bevatten
NL7903400A (nl) Werkwijze voor de bereiding van alpha,beta-onverzadigde n-gesubstitueerde carbonzuuramiden.
NL174568C (nl) Werkwijze voor de bereiding van een tegen tumoren werkzaam polysaccharide en werkwijze voor de bereiding of vervaardiging van een farmaceutisch preparaat dat dat bevat.
IT1124572B (it) Sistema per la trasmissione di medicinale in microparticelle
NL7703237A (nl) Werkwijze voor de bereiding van een veterinair geneesmiddel.
GB2073747B (en) Triazolopyridinone compounds process for the preparation thereof and pharmaceutical preparations containing them
NL7703236A (nl) Werkwijze voor de bereiding van een veterinair geneesmiddel.
NL189253C (nl) Werkwijze voor de bereiding van 2-mercapto-1-ethanol.
NL186699C (nl) Kanamycine-derivaten, werkwijze voor de bereiding daarvan, werkwijze voor de bereiding van farmaceutische preparaten en gevormde farmaceutische preparaten.
NL179053C (nl) N-gesubstitueerde moranolinederivaten, werkwijze voor de bereiding ervan, alsmede werkwijze voor de bereiding van een geneesmiddel met een dergelijk derivaat erin.
NL7613398A (nl) Werkwijze voor de bereiding van nieuwe genees- middelen en aldus verkregen geneesmiddelen.
NL7405072A (nl) Werkwijze ter bereiding van een geneesmiddel, zo gevormd geneesmiddel en werkwijze voor de bereiding van daartoe geschikte geneeskrachtige verbindingen.
NL7903929A (nl) Verbindingen met anti-vitamine d activiteit, farmaceutisch preparaat, dat een dergelijke verbinding bevat, alsmede werkwijze voor de toepassing van dergelijke verbindingen.
ATE21212T1 (de) Medizinisches praeparat und verfahren zu dessen herstellung.
NL7904261A (nl) Werkwijze voor de bereiding van weiprodukten.
YU42763B (en) Process for the hydrolysis of inulin

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
NP1 Patent granted (not automatically)
V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20030525